Oligonucleotide Therapeutics Society Inc
| Fiscal year | Revenue | Expenses | Net | Reserve mo. | Staff % |
|---|---|---|---|---|---|
| 2012 | 354,659 | 341,964 | 12,695 | 3.1 | 0% |
| 2013 | 419,112 | 364,708 | 54,404 | 4.7 | 0% |
| 2014 | 583,947 | 406,918 | 177,029 | 9.3 | 0% |
| 2015 | 656,604 | 453,127 | 203,477 | 13.8 | 0% |
| 2016 | 688,648 | 521,105 | 167,543 | 15.8 | 0% |
| 2017 | 629,580 | 505,203 | 124,377 | 19.2 | 0% |
| 2018 | 822,106 | 667,627 | 154,479 | 17.3 | 0% |
| 2019 | 844,284 | 830,066 | 14,218 | 14.1 | 0% |
| 2020 | 601,451 | 313,631 | 287,820 | 48.2 | 0% |
| 2021 | 788,991 | 388,431 | 400,560 | 52.5 | 0% |
| 2022 | 1,230,167 | 1,077,810 | 152,357 | 20.2 | 0% |
| 2023 | 1,561,718 | 1,644,646 | −82,928 | 12.7 | 0% |
In its most recent public year (2023), this organization spent $82,928 more than it brought in. Its reserves stood at about 12.7 months of spending, up from 3.1 in 2012. Staff pay was 0% of spending.
Reserve months = net assets ÷ average monthly spending; net assets count everything the organization owns beyond its debts — buildings and donor-restricted funds included, not just cash. Staff pay = salaries, wages, and officer compensation; it excludes benefits and payroll taxes. The IRS releases this data years after the fact — this organization's newest public year is 2023. Years refer to the calendar year in which the organization's fiscal year ended. Short-form filers do not publicly report donor-restricted balances or staffing costs. Source filings
Oligonucleotide Therapeutics Society Inc's IRS filings as a feed — one entry per filing year, through 2023. Add the address to any feed reader; in Slack, send /feed subscribe with it (pasting the link alone won't subscribe). How this feed works